Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
Fairly priced — no edge either way.
Close to fair value. Not a bargain, not a rip-off. Come back if the price moves.
The five checks
3 good · 2 caution
- CautionRoughly fairFair value ~$40 sits close to the $44 price — no real margin of safety either way.
- GoodPrice is in line with its recordPriced for ~6%/yr, roughly what it has delivered (57.4%/yr) — from a depressed FY22 base.
- GoodRevenue still growingUp 19.9% last year — demand isn't the problem.
- GoodCash flow compoundingFree cash flow up ~57.4%/yr — the engine is growing.
- CautionManageable net debtNet debt of $9B — about 2.6× annual free cash flow. Normal for a mature company.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $44 to make sense?
Price is in line with its record.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY25Operating cash flow less capital spending, from the annual report$3.7B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$30.0B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $39.7B
- The business, in today's money$69.7B
- Subtract net debtBorrowings and finance leases less cash and securities− $9.5B
- Divide by the shares on file÷ 1.4945B
Fair value per share$40
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $28 to $59 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $41 | $49 | $59 |
| 9% discount | $34 | $40 | $48 |
| 10% discount | $28 | $34 | $40 |
The blue cell is the published method. Some cells sit above today’s price, some below.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Boston Scientific Corporation's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Boston Scientific that is about $9B, or $6 per share. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $44.34 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Boston Scientific another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →